title: A typical preparation of Francisella tularensis O-antigen yields a mixture of three types of saccharides.
abstract: Tularemia is a severe infectious disease in humans caused by the Gram-negative bacterium Francisella tularensis (Ft). Because of its low infectious dose, high mortality rate, and the threat of its large-scale dissemination in weaponized form, development of vaccines and immunotherapeutics against Ft is essential. Ft lipopolysaccharide (LPS), which contains the linear graded-length saccharide component O-antigen (OAg) attached to a core oligosaccharide, has been reported as a protective antigen. Purification of LPS saccharides of defined length and composition is necessary to reveal the epitopes targeted by protective antibodies. In this study, we purified saccharides from LPS preparations from both the Ft subspecies holarctica live vaccine strain (LVS) and the virulent Ft subspecies tularensis SchuS4 strain using liquid chromatography. We then characterized the fractions using high-resolution mass spectrometry and tandem mass spectrometry. Three types of saccharides were observed in both the LVS and SchuS4 preparations: two consisting of OAg tetrasaccharide repeats attached to one of two core oligosaccharide variants and one consisting of tetrasaccharide repeats only (coreless). The coreless OAg oligosaccharides were shown to contain Qui4NFm (4,6-dideoxy-4-formamido-D-glucose) at the nonreducing end and QuiNAc (2-acetamido-2,6-dideoxy-O-D-glucose) at the reducing end. Purified homogeneous preparations of saccharides of each type will allow mapping of protective epitopes in Ft LPS.
authors.affiliation: Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts 02118, United States.
authors.forename: Qi
authors.initials: Q
authors.lastname: Wang
authors.forename: Xiaofeng
authors.initials: X
authors.lastname: Shi
authors.forename: Nancy
authors.initials: N
authors.lastname: Leymarie
authors.forename: Guillermo
authors.initials: G
authors.lastname: Madico
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Sharon
authors.forename: Catherine E
authors.initials: CE
authors.lastname: Costello
authors.forename: Joseph
authors.initials: J
authors.lastname: Zaia
mesh_terms: D000117:Acetylglucosamine / Q000031:analogs & derivatives / Q000032:analysis / Q000737:chemistry; D002241:Carbohydrates / Q000032:analysis* / Q000737:chemistry; D002851:Chromatography, High Pressure Liquid; D000939:Epitopes / Q000737:chemistry; D005603:Francisella / Q000276:immunology / Q000378:metabolism / Q000472:pathogenicity; D005604:Francisella tularensis / Q000276:immunology / Q000378:metabolism* / Q000472:pathogenicity; D005944:Glucosamine / Q000031:analogs & derivatives / Q000032:analysis / Q000737:chemistry; D006603:Hexuronic Acids / Q000032:analysis / Q000737:chemistry; D019081:O Antigens / Q000737:chemistry* / Q000302:isolation & purification*; D015203:Reproducibility of Results; D013045:Species Specificity; D021241:Spectrometry, Mass, Electrospray Ionization; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D053719:Tandem Mass Spectrometry
chemical_list: D002241:Carbohydrates; D000939:Epitopes; D006603:Hexuronic Acids; D019081:O Antigens; C070625:2-acetamido-2,6-dideoxyglucose; C043906:2-acetamido-2-deoxygalacturonamide; D005944:Glucosamine; D000117:Acetylglucosamine
references.citation: J Am Chem Soc. 2003 Dec 31;125(52):16213-9
references.pmid: 14692762
references.citation: J Infect Dis. 1977 Jan;135(1):55-60
references.pmid: 833449
references.citation: Anal Chem. 2010 Jan 15;82(2):516-22
references.pmid: 20000724
references.citation: Vaccine. 2001 Aug 14;19(31):4465-72
references.pmid: 11483272
references.citation: Ann N Y Acad Sci. 2007 Jun;1105:1-29
references.pmid: 17395726
references.citation: Anal Biochem. 1995 Mar 1;225(2):321-7
references.pmid: 7762798
references.citation: Mol Microbiol. 2010 Nov;78(4):820-36
references.pmid: 20662782
references.citation: PLoS One. 2010 Jul 06;5(7):e11060
references.pmid: 20625403
references.citation: J Clin Microbiol. 1991 Jul;29(7):1407-12
references.pmid: 1885735
references.citation: Ann N Y Acad Sci. 2007 Jun;1105:378-404
references.pmid: 17468229
references.citation: Methods Enzymol. 1994;235:242-52
references.pmid: 8057898
references.citation: J Am Soc Mass Spectrom. 2011 Jun;22(6):997-1013
references.pmid: 21953041
references.citation: Hybridoma (Larchmt). 2011 Feb;30(1):19-28
references.pmid: 21466282
references.citation: Anal Chem. 2007 Apr 1;79(7):2901-10
references.pmid: 17328529
references.citation: J Hyg (Lond). 1977 Aug;79(1):47-60
references.pmid: 267668
references.citation: Immunol Lett. 2007 Oct 15;112(2):92-103
references.pmid: 17764754
references.citation: J Med Microbiol. 2005 Jul;54(Pt 7):693-695
references.pmid: 15947437
references.citation: J Immunol. 1961 Oct;87:415-25
references.pmid: 13889609
references.citation: Ann N Y Acad Sci. 2007 Jun;1105:30-66
references.pmid: 17435120
references.citation: J Chem Technol Biotechnol. 1994 Apr;59(4):315-20
references.pmid: 7764815
references.citation: Future Microbiol. 2011 Apr;6(4):391-405
references.pmid: 21526941
references.citation: Ann N Y Acad Sci. 2007 Jun;1105:202-18
references.pmid: 17395723
references.citation: J Med Microbiol. 2003 Oct;52(Pt 10):845-851
references.pmid: 12972577
references.citation: Eur J Biochem. 2002 Dec;269(24):6112-8
references.pmid: 12473106
references.citation: Vaccine. 1994 Jul;12(9):773-5
references.pmid: 7975855
references.citation: JAMA. 2001 Jun 6;285(21):2763-73
references.pmid: 11386933
references.citation: Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9528-33
references.pmid: 15210983
references.citation: Vaccine. 2009 Nov 5;27 Suppl 4:D48-51
references.pmid: 19837286
references.citation: Arch Intern Med. 1961 May;107:702-14
references.pmid: 13746667
references.citation: Carbohydr Res. 1991 Jul 30;214(2):289-97
references.pmid: 1769021